CSE Bulletin: Suspensions - ADMT, ABRT, CFT, GAIA, IWIN, PKG, POLE, PRTI, RWB, CALM, RVR, VEJI

CSE Bulletin: Suspensions - ADMT, ABRT, CFT, GAIA, IWIN, PKG, POLE, PRTI, RWB, CALM, RVR, VEJI

Effective immediately, the following companies are suspended pursuant to CSE Policy 3. The suspensions are considered Regulatory Halts as defined in National Instrument 23-101 Trading Rules. Cease Trade Orders have been issued by one or more securities commissions.

For more information about Cease Trade Orders, visit the Canadian Securities Administrators Cease Trade Order database at www.securities-administrators.ca.

_________________________________

En vigueur immédiatement, les sociétés suivantes sont suspendues conformément à la politique 3 du CSE. Les suspensions sont considérées comme des arrêts réglementaires au sens du Règlement 23-101 sur les règles de négociation. Un ordre d'interdiction d'opérations a été émis par une ou plusieurs commissions des valeurs mobilières.

Pour en savoir plus sur les ordonnances d'interdiction d'opérations, visitez la base de données des ordonnances d'interdiction d'opérations des Autorités canadiennes en valeurs mobilières à www.securities-administrators.ca.

Company Name/Nom de la compagnie :

Symbol/

Symbole:

Securities Commission/Commission des Valeurs Mobilières
Adamant Holding Inc. ADMT British Columbia Securities Commission and Ontario Securities Commission
Albert Labs International Corp. ABRT British Columbia Securities Commission and Ontario Securities Commission
Craftport Cannabis Corp. CFT British Columbia Securities Commission and Ontario Securities Commission
Gaia Grow Corp. GAIA British Columbia Securities Commission and Ontario Securities Commission
Irwin Naturals Inc. IWIN British Columbia Securities Commission and Ontario Securities Commission
ParcelPal Logistics Inc. PKG British Columbia Securities Commission and Ontario Securities Commission
Polaris Northstar Capital Corp. POLE British Columbia Securities Commission and Ontario Securities Commission
PR Technology Inc. PRTI British Columbia Securities Commission and Ontario Securities Commission
Red White & Bloom Brands Inc. RWB British Columbia Securities Commission and Ontario Securities Commission
Revitalist Lifestyle and Wellness Ltd. CALM British Columbia Securities Commission and Ontario Securities Commission
Rift Valley Resources Corp. RVR British Columbia Securities Commission and Ontario Securities Commission
Veji Holdings Ltd. VEJI British Columbia Securities Commission and Ontario Securities Commission

 

If you have any questions or require further information please contact Listings at (416) 367-7340 or E-mail: Listings@thecse.com.

Si vous avez des questions ou si vous avez besoin d'informations supplémentaires, veuillez contacter le service des inscriptions au 416 367-7340 ou par courriel l'adresse: Listings@thecse.com.

News Provided by Newsfile via QuoteMedia

ABRT:CNX
The Conversation (0)
Albert Labs

Albert Labs

Innovative medicines for patients with urgent and unmet needs

CSE Bulletin: Reinstatement - Albert Labs International Corp.

CSE Bulletin: Reinstatement - Albert Labs International Corp.

Effective immediately, Albert Labs International Corp. will be reinstated for trading. The Company has rectified the situation that gave rise to the suspension. _________________________________ Avec effet immédiat, Albert Labs International Corp. sera réintégré aux fins de négociation. La... Keep Reading...
Canadian Investment Regulatory Organization Trade Resumption - ABRT

Canadian Investment Regulatory Organization Trade Resumption - ABRT

Trading resumes in: Company: Albert Labs International Corp. CSE Symbol: ABRT All Issues: Yes Resumption (ET): 12:00 PM CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and... Keep Reading...
Albert Labs Receives preliminary acceptance of 35 Novel Inventive Claims for Patent Protected Manufacturing Technology

Albert Labs Receives preliminary acceptance of 35 Novel Inventive Claims for Patent Protected Manufacturing Technology

Albert Labs has received preliminary acceptance of 35 novel inventive claims as part of its published International PCT Patent Application (No. PCT/CA2022/051281). The Company's proprietary manufacturing methodology, developed and validated in-house at Albert Labs' Vancouver facility,... Keep Reading...
Albert Labs announces Private Placement - April 24, 2023

Albert Labs announces Private Placement - April 24, 2023

Albert Labs has announced a private placement for gross proceeds of up to CAD $3,000,000 , with the first tranche offered at CAD $0.08 /Unit 80% of the Company's First In-Human trial has funding arranged, including a cash rebate from the Australian Government for an estimated CAD $1,200,000... Keep Reading...
Albert Labs announces Strategic Investment from Cantheon Capital LLC for First In-Human Trials

Albert Labs announces Strategic Investment from Cantheon Capital LLC for First In-Human Trials

Highlights: Cantheon Capital, one of the largest global pharmaceutical psychedelics venture capital firms, sign terms for ~CA$830,000 (£500,000) of funding to Albert Labs , allocated towards its first in-human clinical trials in 2023 Albert Labs is nearing their first in-human studies on its... Keep Reading...
Lobe Sciences Ltd. to Attend the ArcStone-Kingswood Growth Summit 2025 in Toronto

Lobe Sciences Ltd. to Attend the ArcStone-Kingswood Growth Summit 2025 in Toronto

lobe sciences ltd. (CSE: LOBE,OTC:LOBEF) (OTCQB: LOBEF) (FSE: LOBE.F) ("Lobe Sciences" or the "Company") a clinical stage biopharmaceutical company focused on developing products to treat diseases with significant unmet medical needs is pleased to announce its participation in the upcoming... Keep Reading...
Dried mushrooms and capsules aligned on a light surface.

Psychedelics Market Update: H1 2025 in Review

The market for psychedelic drugs is emerging as a strategic investment opportunity in healthcare, with forecasts generally placing its value at around US$6.4 billion in 2025. This burgeoning sector is set for robust, double-digit compound annual growth, significantly driven by North America,... Keep Reading...
Glowing mushrooms with colorful graphs in the background on a dark surface.

US Policy Momentum, Clinical Progress Fueling Psychedelics Market in 2025

When the US Food and Drug Administration (FDA) rejected Lykos Therapeutics’ new drug application for MDMA-assisted therapy last August, the initial disappointment cast a shadow over the psychedelics industry. However, the sector is seeing a resurgence of optimism in 2025 on the back of various... Keep Reading...
AVECHO BIOTECHNOLOGY

Avecho and Sandoz enter Exclusive License and Development Agreement to Commercialise CBD for Insomnia in Australia

Avecho Biotechnology Limited (ASX: AVE) (“Avecho” or the “Company”) today announced it has signed an exclusive ten-year development and licensing agreement with Sandoz Group AG (“Sandoz”) for the commercial rights to Avecho’s Phase III cannabidiol (“CBD”) capsule for insomnia in Australia.... Keep Reading...

Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025

Compass management will host a conference call at 8:00 am ET (1:00pm UK) Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the fourth... Keep Reading...
Sunlit mushrooms growing on forest floor, backlit to show vibrant gills and earthy texture.

Psychedelics Market Forecast: Top Trends for Psychedelics in 2025

The psychedelics investment landscape enters 2025 on a complex path marked by both progress and setbacks. While the US Food and Drug Association (FDA) continues to support research into the therapeutic potential of psychedelics, translating promising findings into approved treatments and... Keep Reading...

Latest Press Releases

Related News